Invasive meningococcal disease report, 2012 to 2019

Volume 48-5, May 2022: Vector-Borne Infections–Part 1: Ticks & Mosquitoes

Download this article as a PDF
Published by: The Public Health Agency of Canada
Issue: Volume 48-5, May 2022: Vector-Borne Infections–Part 1: Ticks & Mosquitoes
Date published: May 2022
ISSN: 1481-8531

Subscribe to CCDR

Submit a manuscript

Information for authors

About CCDR

Browse

Past issues

Volume 48-5, May 2022: Vector-Borne Infections–Part 1: Ticks & Mosquitoes

Epidemiologic Study

Epidemiology of invasive meningococcal disease in Canada, 2012–2019

Myriam Saboui¹, Raymond SW Tsang², Robert MacTavish¹, Amisha Agarwal¹, Y Anita Li¹, Marina I Salvadori¹, Susan G Squires¹

Affiliations

¹ Centre for Immunisation and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON

² National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

Correspondence

vpd-mev@phac-aspc.gc.ca

Suggested citation

Saboui M, Tsang RSW, MacTavish R, Agarwal A, Li YA, Salvadori MI, Squires SG. Epidemiology of invasive meningococcal disease in Canada, 2012–2019. Can Commun Dis Rep 2022;48(5):228–36. https://doi.org/10.14745/ccdr.v48i05a06

Keywords: epidemiology, meningococcal, invasive meningococcal disease, Canada

Abstract

Background: A variety of routine childhood and adolescent meningococcal vaccination programs using monovalent (serogroup C) and quadrivalent (A, C, Y, W) conjugate vaccines have been implemented in Canada since 2002, resulting in a decrease in invasive meningococcal disease (IMD) incidence, particularly in serogroup C. Meningococcal vaccines have also been used for outbreak response, including the multicomponent vaccine serogroup B vaccine. This report describes the epidemiology of IMD in Canada from 2012 to 2019.

Methods: Case data were obtained from the National Enhanced IMD Surveillance System between January 1, 2012 and December 31, 2019. Isolates were sent to the National Microbiology Laboratory for confirmation of serogroup and further studies including phenotype and clonal complex identification.

Results: A total of 983 cases of IMD were reported between 2012 and 2019. Overall, the age-adjusted incidence of IMD from 2012 to 2019 was 0.34 cases per 100,000 population per year when standardized to the Canadian 2011 population age distribution (95% CI: 0.32–0.36). Infants younger than one year of age had the highest average age-specific incidence rate (3.6 cases per 100,000 population per year, 95% CI: 2.8–4.3). The highest age-adjusted incidence rate was associated with serogroup B (0.17 cases per 100, 000 population per year, 95% CI: 0.16–0.19). Prior to 2015, most invasive serogroup W isolates were identified as clonal complex 22 (ST-22 CC) and the increase in serogroup W in Canada in recent years has been associated with the replacement of the endemic ST-22 CC with the hyper-virulent ST-11 CC.

Conclusion: Invasive meningococcal disease is a rare but severe infection in Canada that mostly affects the very young. Serogroup B continues to account for the greatest proportion of disease. Serogroup W associated with ST-11 CC is becoming a growing contributor of disease in all age groups not protected by serogroup W-containing vaccines.

Introduction

Invasive meningococcal disease (IMD) is a serious illness caused by the bacterium Neisseria meningitidis^{Footnote 1}. High-risk groups for contracting infection include travellers to endemic areas including the sub-Saharan African meningitis belt, young children, adolescents and individuals living in crowded quarters^{Footnote 2}. Invasive meningococcal disease caused by some serogroups is vaccine preventable and endemic in Canada, with increased activity occurring periodically in the winter months. Since the early 2000s, a variety of routine childhood and adolescent vaccination programs using monovalent (serogroup C) and quadravalent (serogroup A, C, Y and W-135) meningococcal conjugate vaccines have been implemented in Canada^{Footnote 3}. This has resulted in a decrease in IMD incidence, particularly for serogroup C. In the last decade, the multicomponent meningococcal B vaccine (4CMenB) has been used to control outbreaks^{Footnote 3} but has not been used in routine vaccination programs across the country. During the period covered in this report, the schedule of publicly funded vaccination programs has remained constant.

The last national IMD surveillance report described the epidemiology of IMD in Canada from 2006 to 2011. This article focuses on recent IMD data from 2012 to 2019 and explores trends over time, seasonality, spatial distribution and clinical presentation of cases and mortality.

Methods

Data

National enhanced case-based surveillance has been conducted in Canada since 1995 through the Public Health Agency of Canada's Enhanced Invasive Meningococcal Disease Surveillance System (eIMDSS). Provincial and territorial health departments voluntarily reported non-nominal epidemiologic data on confirmed IMD cases on an annual basis. Deterministic matching was conducted to retrospectively link epidemiologic and laboratory data. This article is based on IMD data extracted from eIMDSS, with disease onset between January 1, 2012, and December 31, 2019. See Annex for the national case definition.

Laboratory methods

Isolates were routinely sent to the National Microbiology Laboratory (NML) for confirmation of serogroup and further strain characterization. Serogrouping was done by bacterial agglutination test and confirmed by polymerase chain reaction (PCR) when necessary; serosubtypes of isolates were determined by whole cell enzyme-linked immunosorbent assay using monoclonal antibodies, while clonal analysis was done by multi-locus sequence typing as previously described^{Footnote 4}.

Statistical analysis

The demographic, temporal and spatial distribution of IMD cases were examined, in addition to case manifestation, vaccination history, disease outcome and isolate characteristics. Incidence rates were calculated per 100,000 population using annual July 1^st population estimates by province/territory, age and sex, which were obtained from Statistics Canada^{Footnote 5}. The direct method was used for calculating age-standardized rates based on the 2011 Canadian census. Cases with missing age were excluded from the age standardization and all age-related analyses. Confidence intervals (CIs) for incidence rates were calculated at the 95% confidence level. The CIs of age-standardized rates were calculated according to the method based on the gamma distribution. All analyses were conducted using Microsoft Excel 2010, SAS 9.4, and R version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria).

Results

Trends over time

A total of 983 cases of IMD were reported between 2012 and 2019. Seven cases were excluded from age-specific analyses as the age was missing. The yearly number of reported cases ranged from 98 in 2016 to 154 in 2012 (Figure 1). Overall, the age-adjusted incidence of IMD from 2012 to 2019 was 0.34 cases per 100,000 population per year (95% CI: 0.32–0.36). As shown in Table 1, those patients 40 years of age and older accounted for 42% of all IMD cases between 2012 and 2019, followed by those 15–19 years (12%), 1–4 years (12%) and younger than one year of age (11%). Among serogroup B cases, children 1–4 years of age accounted for the largest proportion of cases (n=90/487, 18%), although those younger than one year of age and 60 years and older followed closely behind (15% of total cases for each age group). Adults over 40 years of age accounted for the majority of cases associated with serogroups C, W-135 and Y (55%, 56% and 63%, respectively).

**Figure 1: Number of invasive meningococcal disease cases and overall incidence rates (per 100,000 population) in Canada by year, 2012–2019**

Year	Cases	Crude rate	Crude rate per 100,000	Adjusted rate	Adjusted rate per 100,000
2012	154	0.0000044617	0.446	0.0000044685	0.447
2013	121	0.0000034687	0.347	0.0000034656	0.347
2014	101	0.0000028653	0.287	0.0000028971	0.290
2015	108	0.0000030358	0.304	0.0000030541	0.305
2016	98	0.0000027041	0.270	0.0000026803	0.268
2017	119	0.0000032770	0.328	0.0000032782	0.328
2018	143	0.0000037240	0.372	0.0000037080	0.371
2019	139	0.0000037254	0.373	0.0000037239	0.372

Table 1: Number and proportion of invasive meningococcal disease cases in Canada for each serogroup by age group, 2012–2019 (N=983 cases)
Age group (years)	Number and proportion of invasive meningococcal disease cases
	Serogroup								Non-groupable		Other^{Table 1 Footnote a}		Unknown^{Table 1 Footnote b}		Total
	B		C		W-135		Y		Non-groupable		Other^{Table 1 Footnote a}		Unknown^{Table 1 Footnote b}		Total
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
<1	73	15	4	7	18	10	5	3	0	0	0	0	9	17	109	11
1–4	90	18	2	4	11	6	3	2	0	0	0	0	9	17	115	12
5–9	18	4	2	4	2	1	2	1	0	0	2	18	2	4	28	3
10–14	20	4	2	4	2	1	3	2	0	0	1	9	2	4	30	3
15–19	69	14	4	7	13	8	26	13	1	25	1	9	6	11	120	12
20–24	36	7	4	7	11	6	19	10	0	0	4	36	3	6	77	8
25–29	21	4	0	0	7	4	6	3	0	0	1	9	2	4	37	4
30–39	23	5	7	13	7	4	8	4	1	25	0	0	4	8	50	5
40–59	62	13	13	23	33	19	44	22	1	25	2	18	10	19	165	17
60+	75	15	18	32	63	37	82	41	1	25	0	0	6	11	245	25
Unknown	0	0	0	0	5	3	2	1	0	0	0	0	0	0	7	1
Total	487	–	56	–	172	–	200	–	4	–	11	–	53	–	983	–
Table 1 Abbreviations Abbreviation: –, not obtained Table 1 Footnote a Other are those cases with the serogroup noted as: A, E, Z, 29E and non-encapsulated Return to Table 1 Footnote a referrer Table 1 Footnote b Unknown are those cases missing serogroup information Return to Table 1 Footnote b referrer

The highest incidence rate observed was associated with serogroup B in 2012 (0.32 cases per 100,000, 95% CI: 0.26–0.38) (Table 2); since then, the rate has declined. The incidence rate for serogroups C and Y has remained low and stable throughout 2012–2019. In more recent years, the incidence rate was highest for serogroup W-135 (0.15 cases per 100,000, 95% CI: 0.11–0.19 in 2018 and 0.12 cases per 100,000, 95% CI: 0.09–0.16 in 2019).

Table 2: Age-standardized incidence rates (per 100,000 population) and 95% CI of invasive meningococcal disease in Canada by serogroup and year, 2012–2019 (N=976 cases^{Table 2 Footnote a})
Serogroup	Age-standardized incidence rates (per 100,000 population)
	2012		2013		2014		2015		2016		2017		2018		2019
	Mean	95% CI	Mean	95% CI	Mean	95% CI	Mean	95% CI	Mean	95% CI	Mean	95% CI	Mean	95% CI	Mean	95% CI
B	0.32	0.26–0.38	0.23	0.18–0.29	0.16	0.12–0.20	0.18	0.14–0.23	0.13	0.09–0.17	0.14	0.10–0.18	0.12	0.08–0.16	0.12	0.09–0.16
C	0.04	0.02–0.06	0.02	0.01–0.04	0.03	0.01–0.05	0.01	0.0–0.03	0.01	0.0–0.02	0.02	0.01–0.05	0.02	0.01–0.04	0.01	0.0–0.03
W-135	0.01	0.0–0.03	0.01	0.0–0.03	0.02	0.01–0.04	0.03	0.01–0.05	0.04	0.02–0.06	0.08	0.05–0.11	0.15	0.11–0.19	0.12	0.09–0.16
Y	0.05	0.03–0.08	0.07	0.04–0.10	0.08	0.06–0.12	0.07	0.05–0.10	0.07	0.04–0.10	0.06	0.03–0.09	0.07	0.05–0.11	0.08	0.05–0.11
Non-groupable	–	–	–	–	–	–	0.01	0.0–0.02	–	–	–	–	–	–	0.01	0.0–0.02
Other^{Table 2 Footnote b}	–	–	–	–	–	–	–	–	0.01	0.0–0.02	0.01	0.0–0.02	–	–	0.01	0.0–0.02
Unknown^{Table 2 Footnote c}	0.03	0.01–0.05	0.01	0.0–0.03	0.01	0.0–0.02	0.01	0.0–0.03	0.02	0.01–0.04	0.03	0.01–0.05	0.01	0.01–0.03	0.03	0.0–0.05
Table 2 Abbreviations Abbreviations: CI, confidence interval, –, not obtained Table 2 Footnote a Seven cases of total sample were missing age Return to Table 2 Footnote a referrer Table 2 Footnote b Other are those cases with the serogroup noted as: A, E, Z, 29E and non-encapsulated Return to Table 2 Footnote b referrer Table 2 Footnote c Unknown are those cases missing serogroup information Return to Table 2 Footnote c referrer

As seen in Table 3, there was a statistically significant decrease in the overall age-standardized incidence rates from 2012 to 2016 (approximate decrease of 0.040 cases per year, 95% CI: 0.003–0.077). The opposite was true from 2016 to 2019, where the overall age-standardized incidence rate increased by 0.038 cases per year (95% CI: −0.005–0.076), although this increase was not statistically significant. Infants younger than one year of age had the highest average age-specific incidence rate of 3.6 cases per 100,000 population per year (95% CI: 2.8–4.3), while the incidence ranged from 0.13 to 0.93 per 100,000 population for the other age groups.

Table 3: Incidence rates (per 100,000 population) of invasive meningococcal disease in Canada by age group and year, 2012–2019 (N=976 cases^{Table 3 Footnote a})
Age group (years)	Incidence rates (per 100,000 population) by year
	2012	2013	2014	2015	2016	2017	2018	2019	2012–2019
	2012	2013	2014	2015	2016	2017	2018	2019	Mean	95% CI
<1	3.42	3.65	4.96	2.86	1.56	3.38	4.20	4.46	3.56	2.83–4.29
1–4	1.18	1.17	0.97	0.91	0.84	0.51	0.83	1.02	0.93	0.78–1.08
5–9	0.44	0.27	0.10	0.05	0.20	0.20	0.05	0.15	0.18	0.09–0.27
10–14	0.68	0.16	0.11	0.21	0.10	0.16	0.05	0.10	0.20	0.06–0.34
15–19	1.17	0.73	0.84	0.66	0.52	0.71	0.47	0.47	0.70	0.54–0.86
20–24	0.51	0.25	0.17	0.33	0.25	0.79	0.37	0.53	0.40	0.26–0.54
25–29	0.25	0.25	0.12	0.12	0.16	0.08	0.12	0.39	0.19	0.12–0.26
30–39	0.13	0.13	0.06	0.15	0.10	0.10	0.16	0.20	0.13	0.10–0.16
40–59	0.31	0.16	0.18	0.20	0.13	0.15	0.31	0.20	0.20	0.15–0.25
60+	0.28	0.42	0.22	0.33	0.41	0.42	0.52	0.42	0.38	0.31–0.44
Overall: crude	0.45	0.35	0.29	0.30	0.27	0.33	0.37	0.37	0.34	0.34
Overall: age-standardized	0.45 (0.38–0.52)	0.35 (0.29–0.41)	0.29 (0.24–0.35)	0.31 (0.25–0.37)	0.27 (0.22–0.33)	0.33 (0.27–0.39)	0.37 (0.31–0.44)	0.37 (0.31–0.44)	0.34 (0.32–0.36)	0.34 (0.32–0.36)
Table 3 Abbreviations Abbreviation: CI, confidence interval Table 3 Footnote a N=7 cases of total sample missing age Return to Table 3 Footnote a referrer

Spatial distribution of cases

Between 2012 and 2019, age-standardized incidence rates were highest in the territory of Nunavut (1.40 cases per 100,000 population per year, 95% CI: 0.59–5.86), which was significantly higher than British Columbia, Alberta, Saskatchewan, Manitoba, Québec and Ontario (Figure 2); however, only eight cases were reported in Nunavut between 2012 and 2019 resulting in wide 95% CIs. Ontario had the lowest age-standardized incidence rate at 0.23 cases per 100,000 population per year (95% CI: 0.20–0.26), which was significantly lower than Québec, Manitoba, Nova Scotia, New Brunswick, Nunavut and British Columbia. Overall, the provinces and territories had comparable age-standardized incidence rates.

**Figure 2: Age-standardized incidence rates (per 100,000 population-year, with 95% CIs) of invasive meningococcal disease in Canada by province or territory, 2012–2019 (N=976 cases)**

Province/territory	Age-standardized incidence rates	95% CI lower interval	95% CI upper interval
BC	0.36	0.30	0.42
NU	1.40	0.59	5.86
YK	0.29	0.007	2.16
NT	0.68	0.14	3.02
NL	0.33	0.17	0.59
PE	0.18	0.02	0.70
NB	0.49	0.33	0.72
NS	0.46	0.31	0.65
AB	0.32	0.26	0.39
SK	0.20	0.12	0.32
MB	0.41	0.30	0.55
QC	0.51	0.46	0.57
ON	0.23	0.20	0.26

Travel and seasonality

Between 2012 and 2019, 51 cases out of 376 cases with available data (14%) were associated with travel. Approximately half of the cases (n=27/51, 53%) travelled within Canada. The United States accounted for the largest proportion of cases associated with travel outside the country (n=5/51, 10%).

Data on month of onset were reported for 930 cases (95% of total sample). Overall, the fall and winter months accounted for the majority of cases (60%). Peaks of IMD onset were observed in the months of December/January (22%), March (12%) and October (10%). The summer months (July and August) were characterized by low IMD activity, with only 11% of all cases reported during the summer.

Clinical presentation and severity

Clinical presentation data were available for 532 samples (51% of total sample), of which 278 cases (52%) presented with meningitis, 182 (34%) with septicemia/bacteremia, 12 (2%) with septicemia/arthritis and 60 (11%) with other manifestations (Table 4). Among the 17 cases with “other manifestations” reported, the most frequently reported clinical presentations were fever (35%), pneumonia (24%) and purpura rash (18%). Meningitis was the most common clinical presentation among all serogroups, except for serogroup W-135 where septicemia/bacteremia was most common.

Table 4: Number and proportion of invasive meningococcal disease cases in Canada with a clinical presentation by serogroup, (N=503)
Serogroup	Number and proportion of invasive meningococcal disease cases^{Table 4 Footnote a}
	Meningitis		Septicemia/bacteremia		Septicemia/arthritis		Other		Total
	n	%	n	%	n	%	n	%	Total
B	135	64	53	25	2	1	20	10	210
C	24	52	17	37	3	7	2	2	46
W-135	38	36	43	41	3	3	21	20	105
Y	66	47	57	41	4	3	13	9	140
Other^{Table 4 Footnote b}	4	50	4	50	0	0	0	0	8
Non-groupable	0	0	1	100	0	0	0	0	1
Unknown^{Table 4 Footnote c}	11	50	7	32	0	0	4	18	22
Total	278	52	182	34	12	2	60	11	532
Table 4 Footnote a 23 cases presented with two diagnoses and three cases presented with three diagnoses Return to Table 4 Footnote a referrer Table 4 Footnote b Other are those cases with the serogroup noted as: A, E, Z, 29E, and non-encapsulated Return to Table 4 Footnote b referrer Table 4 Footnote c Unknown are those cases missing serogroup information Return to Table 4 Footnote c referrer

Between 2012 and 2019, of the 621 cases with outcome data available (yes/no for death), 86 deaths associated with IMD were reported. This represents an overall case fatality rate of 13.8%. As seen in Figure 3, serogroup B accounted for the majority (52%) of deaths reported. The case fatality rate was highest in those younger than one year of age (19%), followed closely by those 60 years and over (17%) and those aged 20–24 years of age (15%). The proportion of cases who died from IMD was highest in cases for which the positive specimen was blood (n=68/432, 16%) compared with cerebrospinal fluid specimens (n=15/182, 8%) (difference of 8%, 95% CI 1.8–13.1%). Of the 15 cases whose positive specimen was joint fluid, there were no deaths reported.

**Figure 3: Number of invasive meningococcal disease deaths and case fatality ratio by age group and serogroup, Canada, 2012–2019 (N=621^{Figure 3 Footnote a})**

Other	Unknown	Other+Unknown	Total deaths	Total n (yes or no)	Proportion	Case fatality
0	3	3	14	74	19%	18.91891892
0	0	0	9	73	12%	12.32876712
1	0	1	2	17	12%	11.76470588
0	0	0	1	19	5%	5.263157895
0	0	0	11	77	14%	14.28571429
0	0	0	8	53	15%	15.09433962
0	0	0	1	22	5%	4.545454545
0	1	1	2	30	7%	6.666666667
0	1	1	13	105	12%	12.38095238
0	2	2	25	151	17%	16.55629139

Strain characteristics

Serogroup distribution of culture-confirmed invasive meningococcal disease

The NML received a total of 772 (79%) case isolates of N. meningitidis between 2012 and 2019. Serogroup B was the most common (accounted for 48.9% of all isolates), followed by serogroup Y (23.8%), serogroup W (20.0%) and serogroup C (6.0%), with the remaining 1.3% or 10 isolates identified as serogroup E (three isolates), serogroup Z (two isolates) or non-encapsulated (five isolates). A steady increase in serogroup W was observed over time with 2.7% of the IMD case isolates received at the NML in 2012, to 3.9% in 2013, 4.8% in 2014, 10.1% in 2015, 18.8% in 2016, 27.1% in 2017, 44.7% in 2018 and 39.7% in 2019. By 2018, and into 2019 and 2020 (unpublished data, data for 2020, NML) serogroup W was the most encountered serogroup among all IMD isolates received at the NML.

Serogroup B

No particular clone appeared to predominant in Canada. The most encountered serogroup B clonal complexes (CC) (in order of frequency of occurrence) were sequence type (ST)-269 CC, ST-41/44 CC, ST-213 CC, ST-32 CC, ST-35 CC and ST-1157 CC (each with at least five isolates), which together made up 90% of all the serogroup B IMD isolates from 2012 to 2019. From 2015 to 2019, there were only 189 serogroup B IMD case isolates received at the NML and the most encountered CCs were ST-41/44 CC, ST-269 CC, ST-213 CC, ST-32 CC and ST-1157 CC (each with at least five isolates). Together, they accounted for 84% of all the serogroup B isolates.

Serogroup W

Prior to 2015, most invasive serogroup W isolates were identified as ST-22 CC and the increase in serogroup W in Canada in recent years was associated with the replacement of the endemic ST-22 CC with the hyper-virulent ST-11 CC^{Footnote 6}. They were characterized by the antigenic formula of W:2a:P1.5,2 with most typed as ST-11 and of the sub-lineage 11.1^{Footnote 7}.

Serogroup Y

The ST-23 CC continued to be the most encountered serogroup Y CC, followed by ST-167 CC and ST-174 CC.

Serogroup C

Of the 49 serogroup C IMD case isolates received at the NML, 36 were typed as ST-11 CC and 13 were typed as non-ST-11 CC. Of the 36 ST-11 CC isolates; 15 were further subtyped as the ET-15 type (sub-lineage 11.2), 20 were non-ET-15 type or sub-lineage 11.1 and one was without further subtyping information.

Non-ST-11 CC serogroup C isolates included three typed as ST-1195 (ST-269 CC) and all three were found in Alberta (in 2017, 2018 and 2019) and had the antigenic formula C:NT:P1.9. There were also two serogroup C isolates typed as ST-4821 (ST-4821 CC) and both were found in British Columbia (in 2013 and 2014) and had the antigenic formula C:NT:P1.1. Additionally, there were three serogroup C isolates typed as ST-35 CC, three typed as ST-103 CC, one typed as ST-41/44 CC and one with a sequence type not assigned to any known CC.

Discussion

Since the implementation of publicly funded meningococcal C and meningococcal quadrivalent vaccination programs in Canada, the overall incidence of IMD has decreased significantly. Over the surveillance period, vaccination coverage for the meningococcal conjugate C vaccine has remained stable in children under two years of age, ranging from 87.6% to 88.7% between 2013 and 2017^{Footnote 8}.

The downward trend in incidence was noted across all Canadian regions as early as the year following implementation of publicly funded programs. Between 2012 and 2019, the Prairies and Central regions reached an all-time low incidence rate. Consistent with the previous surveillance report, Nunavut continued to report the highest incidence rate^{Footnote 9}. The overall mean incidence in the previously published surveillance report was 0.58 cases per 100,000 population for 2006–2011 compared with 0.34 cases per 100,000 population for 2012–2019^{Footnote 6}. Serogroup B accounted for the largest proportion of cases, and disproportionately affected infants under the age of one year. Similar to previously published reports, cases of IMD predominated in the winter months with the highest levels in January and March^{Footnote 4}^{Footnote 10}.

Beginning in 2016, the number of IMD cases associated with serogroup W increased by at least 50% every year in Canada. Between 2012 and 2019, the largest proportion of serogroup W cases associated with clonal complex 11 were reported in adults aged 60 years and older. The emergence of serogroup W cases associated with clonal complex 11 has been reported in previous studies^{Footnote 10}^{Footnote 11} and our results are consistent with these findings. The NML also reported on the growing number of serogroup W strains in Canada over time^{Footnote 4}^{Footnote 12}. Genomic isolates of the Canadian serogroup W isolates showed the majority of the recent isolates belonged to the South American strain type or sub-lineage, although a small number isolated up to 2016 belonged to the Hajj-type strain^{Footnote 13}.

During the time period 2012–2019, there were three documented Canadian outbreaks^{Footnote 14}. One outbreak spanned from 2006 to 2013 in the region of Saguenay-Lac-Saint-Jean, Québec, and was due to serogroup B. A vaccination campaign was launched the following year in the region using the 4CMENB vaccine^{Footnote 15}. The incidence of IMD due to serogroup B fell dramatically in the targeted population of the vaccination campaign (up to 20 years of age) and in 2015, an outbreak was reported in a university in Nova Scotia^{Footnote 14}. The first documented outbreak due to serogroup CC-11 was reported in British Columbia in 2017 and resulted in five cases in adolescents aged 15–19 years^{Footnote 14}.

Antibiotic resistant N. meningitidis was recently observed in some serogroup Y isolates that belonged to ST-3587 (ST-23 CC) clone and was characterized by the production of β-lactamase due to presence of the bla_ROB-1 gene likely to be acquired from Haemophilus influenzae^{Footnote 16}. This strain has also been identified in France^{Footnote 17} and in the United States, which led to the release of a health alert in June 2020^{Footnote 16}. In the United States, this strain has also acquired resistance to ciprofloxacin, an antibiotic commonly used for chemoprophylaxis of close contacts of IMD cases^{Footnote 18}. Up to now, the expansion and spread of this clone has not been observed in Canada (unpublished data, NML).

Laboratory surveillance is important for the identification of novel strains that may contribute to the evolving nature of IMD. For example, the novel South American-United Kingdom strain of ST-11 serogroup W has been responsible for the increase in meningococcal W disease globally and has led to reports of unusual clinical presentations^{Footnote 7}^{Footnote 19}^{Footnote 20}. The recent increase in meningococcal C disease in the African meningitis belt was due to a new strain that arose when a ST-10217 non-encapsulated strain from a healthy carrier in Burkina Faso acquired a serogroup C capsule^{Footnote 21}. The recent emergence in the United States of β-lactamase positive serogroup Y N. meningitidis with additional resistance to fluoroquinolones has important implications for treatment and chemoprophylaxis of IMD^{Footnote 22}.

Imported cases via travel accounted for a small proportion of cases, and the majority of cases due to travel were within Canada or the United States. Laboratory characterization of strains identified two potential imported cases with unusual characteristics of C:NT:P1.14, ST-4821 and resistance to ciprofloxacin. These strain characteristics have not been found in any Canadian isolates previously but were commonly associated with a unique serogroup C clone in China^{Footnote 4}, which suggested that these two isolates were from imported cases.

Serogroup B accounted for the largest proportions of clinical presentations. Between 2012 and 2019, the mortality rate associated with IMD continued to decline over time and serogroup B accounted for the majority of deaths. The trends observed in this report are consistent with evidence from other publications^{Footnote 6}. Mortality rates in Canada were comparable to those of Australia and England^{Footnote 7}^{Footnote 13}. Positive specimens from blood resulted in nearly double the mortality ratio when compared with positive specimens from cerebrospinal fluid. This finding was statistically significant.

In recent years, evidence of atypical clinical presentation of IMD serogroup W characterized by gastrointestinal symptoms has been reported across the world^{Footnote 23}^{Footnote 24}^{Footnote 25}^{Footnote 26}. Among the cases reported with other clinical manifestations in Canada between 2012 and 2019, the majority were associated with serogroup W-135. Heightened surveillance of atypical presentations in Canada is recommended to better understand the evolving epidemiology of IMD.

The World Health Organization established a plan to defeat meningitis by 2030^{Footnote 27}. The plan includes three main goals pertaining to epidemics, disease transmission and disabilities and long-term effects of infection: 1) the elimination of IMD epidemics; 2) the reduction of cases and deaths from vaccine preventable bacterial meningitis; and 3) the reduction of disability associated with infections. Although IMD remains endemic in Canada, evidence from this article shows noteworthy reductions in incidence rates in some geographic areas in Canada. The introduction of publicly funded vaccination programs in Canada has sharply decreased the incidence of IMD associated with strains covered by the vaccines. New strains of IMD will continue to pose challenges for disease target reductions such as the ones outlined by the World Health Organization. Canada has a strong public health infrastructure that allows for early detection of cases and the implementation of prompt public health actions; however, the current routine surveillance at the national level does not collect data on cases post-infection, such as long-term disabilities.

Limitations

Several limitations should be noted. First, data reported to the eIMDSS surveillance system are not epidemiologically linked with laboratory data. To connect the two data sources, deterministic matching was done. Some cases may have been missed due to insufficient data to match the two data sources. Second, many cases might not be recognized, as antibiotics are frequently given prior to taking cultures and the organism would not be identified. Third, certain data variables, such as immunization history, were often missing or incomplete. Finally, limited outbreak information represents a gap in national IMD surveillance.

Conclusion

Invasive meningococcal disease is a rare but severe infection that continues to affect the very young population in Canada. While serogroup B continues to account for the greatest proportion of disease, serogroup W associated with CC-11 is becoming a growing contributor of disease in older adults. The evolving nature of N. meningitidis requires a comprehensive approach to its surveillance, which should include a laboratory component that documents strain characteristics.

Authors' statement

MS — Conceptualization, methodology, software, formal analysis, investigation, data curation, writing–original draft, writing–review and editing, visualization

RSWT — Methodology, formal analysis, investigation, data curation, writing–original draft, writing–review and editing, visualization

RM — Methodology, formal analysis, writing–original draft, writing–review and editing

AA — Methodology, formal analysis, writing–original draft, writing–review and editing

YAL — Conceptualization, methodology, review and editing

MIS — Writing–review and editing

SGS — Conceptualization, writing–review and editing

Competing interests

None.

Acknowledgements

The authors acknowledge the Canadian provinces and territories for providing data to the Enhanced Invasive Meningococcal Surveillance System and for providing their input to this report.

Funding

None.

References

Footnote 1

David L. Heymann. Control of Communicable Diseases Manual. 20^th ed. Washington DC, USA: American Public Health Association; 2014. ISBN-10: 087550184.

Return to Footnote 1 referrer

Footnote 2

Public Health Agency of Canada. Invasive Meningococcal Disease. Ottawa (ON): PHAC: 2014 (accessed 2020-10-26). https://www.canada.ca/en/public-health/services/immunization/vaccine-preventable-diseases/invasive-meningococcal-disease/risks.html

Return to Footnote 2 referrer

Footnote 3

National Advisory Committee on Immunization. The Recommended Use of the Multicomponent Meningococcal B (4CMenB) Vaccine in Canada. NACI; (updated 2014; accessed 2022-01-16). https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommended-use-multicomponent-meningococcal-b-4cmenb-vaccine-canada.html#toc_4a

Return to Footnote 3 referrer

Footnote 4

Tsang RS, Deeks SL, Wong K, Marchand-Austin A, Jamieson FB. Invasive serogroup W Neisseria meningitidis (MenW) in Ontario, Canada shows potential clonal replacement during the period January 1, 2009 to June 30, 2016. Can Commun Dis Rep 2016;42(12):263–6. https://doi.org/10.14745/ccdr.v42i12a06

Return to Footnote 4 referrer

Footnote 5

Statistics Canada. Population and demography statistics. Ottawa (ON): StatCan; 2022 (accessed 2022-01-20). https://www.statcan.gc.ca/en/subjects-start/population_and_demography

Return to Footnote 5 referrer

Footnote 6

European Centre for Disease Control. Invasive meningococcal disease. Annual epidemiological report for 2017. Solna (SE): ECDC; 2019. https://www.ecdc.europa.eu/en/publications-data/invasive-meningococcal-disease-annual-epidemiological-report-2017

Return to Footnote 6 referrer

Footnote 7

Government of Australia Department of Health. Invasive Meningococcal Disease National Surveillance Report. Canberra (AU); Government of Australia; 2018 (accessed 2020-10-26). https://www1.health.gov.au/internet/main/publishing.nsf/Content/5FEABC4B495BDEC1CA25807D001327FA/$File/1Oct-31Dec19-qrt3-IMD.pdf

Return to Footnote 7 referrer

Footnote 8

Public Health Agency of Canada. Highlights from the 2019 Childhood National Immunization Coverage Survey (cNICS). Ottawa (ON): PHAC; (updated 2022-02-07). https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/2019-highlights-childhood-national-immunization-coverage-survey.html

Return to Footnote 8 referrer

Footnote 9

Li YA, Tsang R, Desai S, Deehan H. Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011. Can Commun Dis Rep 2014;40(9):160–9. https://doi.org/10.14745/ccdr.v40i09a01

Return to Footnote 9 referrer

Footnote 10

Li YA, Martin I, Tsang R, Squires SG, Demczuk W, Desai S. Invasive Bacterial Diseases in Northern Canada, 2006-2013. Can Commun Dis Rep 2016;42(4):74–80. https://doi.org/10.14745/ccdr.v42i04a01

Return to Footnote 10 referrer

Footnote 11

Booy R, Gentile A, Nissen M, Whelan J, Abitbol V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum Vaccin Immunother 2019;15(2):470–80. https://doi.org/10.1080/21645515.2018.1532248

Return to Footnote 11 referrer

Footnote 12

Tsang R, Hoang L, Tyrrell GJ, Horsman G, Van Caeseele P, Jamieson F, Lefebvre B, Haldane D, Gad RR, German GJ, Zahariadis G. Increase in Neisseria meningitidis serogroup W invasive disease in Canada: 2009-2016. Can Commun Dis Rep 2017;43(7-8):144–9. https://doi.org/10.14745/ccdr.v43i78a01

Return to Footnote 12 referrer

Footnote 13

Public Health England. Invasive meningococcal disease in England: annual laboratory confirmed reports for epidemiological year 2018 to 2019. London (UK): PHE; 2019 (accessed 2020-10-26). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/842368/hpr3819_IMD-ann.pdf

Return to Footnote 13 referrer

Footnote 14

Soumahoro L, Abitbol V, Vicic N, Bekkat-Berkani R, Safadi MA. Meningococcal Disease Outbreaks: A Moving Target and a Case for Routine Preventative Vaccination. Infect Dis Ther 2021;10(4):1949–88. https://doi.org/10.1007/s40121-021-00499-3

Return to Footnote 14 referrer

Footnote 15

De Wals P. Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story. Can J Infect Dis Med Microbiol 2019;2019:8901847. https://doi.org/10.1155/2019/8901847

Return to Footnote 15 referrer

Footnote 16

Lucidarme J, Scott KJ, Ure R, Smith A, Lindsay D, Stenmark B, Jacobsson S, Fredlund H, Cameron JC, Smith-Palmer A, McMenamin J, Gray SJ, Campbell H, Ladhani S, Findlow J, Mölling P, Borrow R. An international invasive meningococcal disease outbreak due to a novel and rapidly expanding serogroup W strain, Scotland and Sweden, July to August 2015. Euro Surveill 2016;21(45):30395. https://doi.org/10.2807/1560-7917.ES.2016.21.45.30395

Return to Footnote 16 referrer

Footnote 17

Tsang RSW, Ahmad T, Tyler S, Lefebvre B, Deeks SL, Gilca R, Hoang L, Tyrrell G, Van Caeseele P, Van Domselaar G, Jamieson FB. Whole genome typing of the recently emerged Canadian serogroup W Neisseria meningitidis sequence type 11 clonal complex isolates associated with invasive meningococcal disease. Int J Infect Dis 2018;69:55–62. https://doi.org/10.1016/j.ijid.2018.01.019

Return to Footnote 17 referrer

Footnote 18

Tsang RSW, Ahmad T, Jamieson FB, Tyrrell GJ. WGS analysis of a penicillin-resistant Neisseria meningitidis strain containing a chromosomal ROB-1 β-lactamase gene. J Antimicrob Chemother 2019;74(1):22–8. https://doi.org/10.1093/jac/dky391

Return to Footnote 18 referrer

Footnote 19

United States Centres for Disease Control and Prevention. Detection of Ciprofloxacin-resistant, β-lactamase-producing Neisseria meningitidis Serogroup Y Isolates, United States, 2019–2020 (accessed 2021-04-09). https://emergency.cdc.gov/han/2020/han00433.asp

Return to Footnote 19 referrer

Footnote 20

McNamara LA, Potts C, Blain AE, Retchless AC, Reese N, Swint S, Lonsway D, Karlsson M, Lunquest K, Sweitzer JJ, Wang X, Hariri S, Fox LM; Antimicrobial-Resistant Neisseria meningitidis Team. Detection of Ciprofloxacin-Resistant, β-Lactamase-Producing Neisseria meningitidis Serogroup Y Isolates - United States, 2019-2020. MMWR Morb Mortal Wkly Rep 2020;69(24):735–9. https://doi.org/10.15585/mmwr.mm6924a2

Return to Footnote 20 referrer

Footnote 21

Campbell H, Parikh SR, Borrow R, Kaczmarski E, Ramsay ME, Ladhani SN. Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016. Euro Surveill 2016;21(12):30175. https://doi.org/10.2807/1560-7917.ES.2016.21.12.30175

Return to Footnote 21 referrer

Footnote 22

Beltrami D, Guilcher P, Longchamp D, Crisinel PA. Meningococcal serogroup W135 epiglottitis in an adolescent patient. BMJ Case Rep 2018;2018:bcr2017223038. https://doi.org/10.1136/bcr-2017-223038

Return to Footnote 22 referrer

Footnote 23

Campbell H, Andrews N, Parikh S, Ribeiro S, Gray S, Lucidarme J, Ramsay ME, Borrow R, Ladhani SN. Variable clinical presentation by the main capsular groups causing invasive meningococcal disease in England. J Infect 2020;80(2):182–9. https://doi.org/10.1016/j.jinf.2019.11.001

Return to Footnote 23 referrer

Footnote 24

Russcher A, Fanoy E, van Olden GD, Graafland AD, van der Ende A, Knol MJ. Necrotising fasciitis as atypical presentation of infection with emerging Neisseria meningitidis serogroup W (MenW) clonal complex 11, the Netherlands, March 2017. Euro Surveill 2017;22(23):30549. https://doi.org/10.2807/1560-7917.ES.2017.22.23.30549

Return to Footnote 24 referrer

Footnote 25

Sudbury EL, O'Sullivan S, Lister D, Varghese D, Satharasinghe K. Case Manifestations and Public Health Response for Outbreak of Meningococcal W Disease, Central Australia, 2017. Emerg Infect Dis 2020;26(7):1355–63. https://doi.org/10.3201/eid2607.181941

Return to Footnote 25 referrer

Footnote 26

Loenenbach AD, van der Ende A, de Melker HE, Sanders EA, Knol MJ. The Clinical Picture and Severity of Invasive Meningococcal Disease Serogroup W Compared With Other Serogroups in the Netherlands, 2015-2018. Clin Infect Dis 2020;70(10):2036–44. https://doi.org/10.1093/cid/ciz578

Return to Footnote 26 referrer

Footnote 27

World Health Organization. Defeating meningitis by 2030. Geneva (CH): WHO; 2021 (accessed 2021-04-25). https://www.who.int/initiatives/defeating-meningitis-by-2030

Return to Footnote 27 referrer

Annex: National case definition of invasive meningococcal disease as of November 2009

Confirmed case

Clinical evidence of invasive disease with laboratory confirmation of infection:

Isolation of Neisseria meningitidis (N. meningitidis) from a normally sterile site (blood, cerebrospinal fluid (CSF], joint, pleural or pericardial fluid)

Demonstration of N. meningitidis DNA by an appropriately validated nucleic acid test (NAT) from a normally sterile site

Probable case

Clinical evidence of invasive disease with purpura fulminans or petechiae, with no other apparent cause and with non-confirmatory laboratory evidence:

Detection of N. meningitidis antigen in the CSF

Note: Positive antigen test results from urine and serum samples are unreliable for diagnosing meningococcal disease.

Clinical evidence

Clinical illness associated with invasive meningococcal disease usually manifests itself as meningitis and/or septicaemia, although other manifestations may be observed (e.g. orbital cellulitis, septic arthritis). Invasive disease may progress rapidly to petechiae or purpura fulminans, shock and death.

Both confirmed and probable cases of disease should be notified as of January 1, 2006.

This work is licensed under a Creative Commons Attribution 4.0 International License

Table of contents

Page details

Date modified:: 2022-05-09

Language selection

Search